Cargando…

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC

INTRODUCTION: In this study, we aim to build radiomics and multiomics models based on transcriptomics and radiomics to predict the response from patients treated with the PD-L1 inhibitor. MATERIALS AND METHODS: One hundred and ninety-five patients treated with PD-1/PD-L1 inhibitors were included. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouhamama, Amine, Leporq, Benjamin, Faraz, Khuram, Foy, Jean-Philippe, Boussageon, Maxime, Pérol, Maurice, Ortiz-Cuaran, Sandra, Ghiringhelli, François, Saintigny, Pierre, Beuf, Olivier, Pilleul, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Radiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365090/ https://www.ncbi.nlm.nih.gov/pubmed/37492391 http://dx.doi.org/10.3389/fradi.2023.1168448

Ejemplares similares

Characterization of Breast Tumors from MR Images Using Radiomics and Machine Learning Approaches
por: Faraz, Khuram, et al.
Publicado: (2023)

MRI-based radiomics to predict lipomatous soft tissue tumors malignancy: a pilot study
por: Leporq, Benjamin, et al.
Publicado: (2020)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022)

Prediction of lipomatous soft tissue malignancy on MRI: comparison between machine learning applied to radiomics and deep learning
por: Fradet, Guillaume, et al.
Publicado: (2022)

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2018)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients
por: Bracci, Stefano, et al.
Publicado: (2021)

Enabling 3D-Liver Perfusion Mapping from MR-DCE Imaging Using Distributed Computing
por: Leporq, Benjamin, et al.
Publicado: (2013)

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2022)

What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
por: Cui, Ruichen, et al.
Publicado: (2022)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
por: Valet, Orion, et al.
Publicado: (2021)

AutoRadiomics: A Framework for Reproducible Radiomics Research
por: Woznicki, Piotr, et al.
Publicado: (2022)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
por: Farina, Benito, et al.
Publicado: (2023)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
por: Perrichet, Anaïs, et al.
Publicado: (2020)

A radiomics approach to the diagnosis of femoroacetabular impingement
por: Montin, Eros, et al.
Publicado: (2023)

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
por: Gobbini, Elisa, et al.
Publicado: (2020)

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
por: Malet, Julie, et al.
Publicado: (2023)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression
por: Masuda, Ken, et al.
Publicado: (2020)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2023)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

A first look into radiomics application in testicular imaging: A systematic review
por: Fanni, Salvatore C., et al.
Publicado: (2023)

The Role of Machine Learning and Radiomics for Treatment Response Prediction in Idiopathic Normal Pressure Hydrocephalus
por: Sotoudeh, Houman, et al.
Publicado: (2021)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study
por: Wu, Minghao, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
por: Chen, Zi‐Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9dqo8ms5h52geerftadqrm7ivr